Nishino, Kazumi http://orcid.org/0000-0003-2000-7472
Fujiwara, Yutaka
Ohe, Yuichiro
Saito, Ryota
Miyauchi, Eisaku
Kobayashi, Tetsu
Nakai, Yasuo
Takahashi, Toshiaki
Shibata, Taro
Hamaguchi, Tetsuya
Kikuchi, Katsuko
Yamazaki, Naoya
Fukuda, Haruhiko
Nozawa, Keiko
Kiyohara, Yoshio
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP17ck0106326)
Article History
Received: 18 May 2020
Accepted: 8 September 2020
First Online: 11 September 2020
Compliance with ethical standards
:
: K. Nishino reports personal fees from AstraZeneca, Chugai pharmaceutical, Eli Lilly Japan, Roche Diagnostics, Novartis, Pfizer, and Ono Pharmaceutical, and grants and personal fees from Nippon Boehringer Ingelheim, Y. Fujiwara reports grants and personal fees from Astra Zeneca, Bristol-Myers Squibb, Chugai Pharma, Daiichi Sankyo, MSD, and Novartis; grants from Abbvie, Eisai, Eli Lilly, Incyte, and Merck Serono; and personal fees from Ono Pharmaceutical. Y. Ohe reports grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Chugai, Eli Lilly, Kyorin, Nippon Kayaku, Novartis, ONO Pharmaceutical, Pfizer, Taiho, and Takeda; personal fees from Boehringer Ingelheim, Celtrion, Amgen, and Janssen; and grants from Ignyta and Kissei. E. Miyauchi reports grants and personal fees from Chugai pharmaceutical and Boehringer Ingelheim. T. Kobayashi reports personal fees from AstraZeneca, Chugai pharmaceutical, Nippon Boehringer Ingelheim, Eli Lilly Japan, Pfizer, and Ono Pharmaceutical. Y. Nakai reports personal fees from ONO Pharmaceutical, Novartis, and Jiho Inc. T. Takahashi reports grants and personal fees from AstraZeneca, Chugai pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, MSD, Pfizer Japan, and Boehringer Ingelheim Japan, and personal fees from Roche Diagnostics. T. Hamaguchi reports personal fees from Takeda Pharmaceutical Co., Ltd. N. Yamazaki reports grants and personal fees from Ono Pharmaceutical, Novartis Pharma K.K., Bristol-Myers Squibb, and Merck Sharp & Dohme; personal fees from Takeda Pharmaceutical and Chugai Pharmaceutical; and grants from Sysmex. Y. Kiyohara reports grants from MSD, Bristol-Myers Squibb, and Takara Bio, and personal fees from Ono Pharmaceutical. All other authors declare that they have no conflicts of interest.
: This study was conducted according to the Declaration of Helsinki and was approved by the ethics review board of each participating institution. Research ethics boards at all participating institutions approved the study protocol.
: Each enrolled patient provided written informed consent.